Clinical trial
A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic…
NCT00115908 · Human Genome Sciences Inc., Industry · Completed
Key facts
| NCT number | NCT00115908 |
|---|---|
| Title | A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1 |
| Official title | A Phase 2b, Randomized, Multi-Center, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 1 |
| Lead sponsor | Human Genome Sciences Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Albuferon, Ribavirin, PEG-IFNalfa2a |
| Enrollment | 458 |
| Start date | May 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jun 27, 2005 |
| Last update posted | Nov 7, 2013 |
| Countries | Australia, Canada, Czechia, France, Germany, Israel, Poland, Romania |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: